SCHEMBL230113

SCHEMBL230113

C1=C(c2ccccc2)COc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.53
ALOX5 P09917 1/20 0.42
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
RARA P10276 2/20 0.38
RARG P13631 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 2/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
KMT2A Q03164 2/20 0.38
RELA Q04206 2/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29518399 1.00 NISCH (0.53) NISCHALOX5NPC1RAB9AMAPT
SCHEMBL26549421 0.85 NISCH (0.48) NISCHALOX5NPC1RAB9AMAPT
SCHEMBL28660144 0.85 MAPT (0.50) NISCHALOX5NPC1RAB9AMAPT
SCHEMBL28660162 0.85 PTGS1 (0.48) NISCHALOX5NPC1RAB9AMAPT
SCHEMBL26053155 0.84 NISCH (0.40) NISCHALOX5NPC1RAB9AMAPT
SCHEMBL616344 0.80 RARA (0.46) NISCHALOX5RAB9AMAPTALDH1A1
SCHEMBL571115 0.79 MAPT (0.45) NISCHALOX5NPC1RAB9AMAPT
SCHEMBL28672526 0.79 ALOX5 (0.46) NISCHALOX5MAPTALDH1A1LMNA
SCHEMBL11230728 0.79 LMNA (0.44) NISCHALOX5NPC1RAB9AMAPT
SCHEMBL30667714 0.78 TLR2 (0.55) NISCHNPC1RAB9AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2699218-B1 USE OF A COMBINATION OF CAROTENOID, PHYTOESTROGEN AND VITAMIN C FOR THE PREVENTION AND/OR TREATMENT OF PIGMENTATION DISORDERS NUTRICOS TECH (FR) 2018-10-17 EP claimed
EP-2900336-B1 ORAL COMPOSITION FOR REINFORCING SKIN TOLERANCE FOLLOWING TOPICAL ADMINISTRATION OF A RETINOID COMPOUND NUTRICOS TECH (FR) 2018-07-25 EP claimed
US-10022315-B2 Oral composition for reinforcing skin tolerance following topical administration of a retinoid compound LABORATOIRES INNEOV (FR) 2018-07-17 US claimed
CN-103641808-B The enantioselective hydrogenation method of chromene GIRINDUS AMERICA INC. (US) 2016-04-20 CN claimed
CN-103755675-B The enantioselective hydrogenation method of chromene GIRINDUS AMERICA INC. (US) 2015-11-18 CN claimed
US-20150258000-A1 ORAL COMPOSITION FOR REINFORCING SKIN TOLERANCE FOLLOWING TOPICAL ADMINISTRATION OF A RETINOID COMPOUND LABORATORIES INNEOV (FR) 2015-09-17 US claimed
EP-1919887-B1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA INC (US) 2015-02-18 EP claimed
US-20140148401-A1 COMBINATION OF CAROTENOID, PHYTOOESTROGEN AND VITAMIN C FOR MOISTURIZING THE SKIN LABORATOIRES INNEOV (FR) 2014-05-29 US claimed
CN-101535286-B Process for the enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC 2014-05-07 CN claimed
US-8716497-B2 Method for enantioselective hydrogenation of chromenes CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2014-05-06 US claimed
US-7960573-B2 Method for enantioselective hydrogenation of chromenes CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2011-06-14 US claimed
US-20100069653-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES Children hospital medical center (US) 2010-03-18 US claimed
CN-101535286-A Process for the enantioselective hydrogenation of chromenes GIRINDUS AMERICA INC (US) 2009-09-16 CN claimed
US-7528267-B2 Method for enantioselective hydrogenation of chromenes GIRINDUS AMERICA, INC. (US) 2009-05-05 US claimed
US-20090105330-A1 ADMIXTURE OF CAROTENOIDS AND ISOFLAVONOIDS FOR TREATING CUTANEOUS SYMPTOMS OF AGING L'OREAL (FR) 2009-04-23 US claimed
EP-1919887-A2 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES Girindus America, Inc. (US) 2008-05-14 EP claimed
WO-2007016423-A2 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES GIRINDUS AMERICA INC. (US) 2007-02-08 WO claimed
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes AUSIO PHARMACEUTICALS, LLC 2007-02-01 US claimed
US-20040071745-A1 Admixture of carotenoids and isoflavonoids for treating cutaneous symptoms of aging SOCIETE L'OREAL S.A. (FR) 2004-04-15 US claimed
US-20020197289-A1 Compositions and methods for combating the appearance of ageing L'OREAL (FR) 2002-12-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020197289-A1 Compositions and methods for combating the appearance of ageing CYP24A1, CYP27B1, CYP2R1 NISCH 1023/4885ALOX5 399/4885NPC1 4444/4885
US-20070027329-A1 Method for enantioselective hydrogenation of chromenes HRH3, HRH2, CHD8 NISCH 1832/4885ALOX5 1095/4885NPC1 4761/4885
US-20100069653-A1 METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES HRH3, HRH2, CHD8 NISCH 1832/4885ALOX5 1095/4885NPC1 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.